The market for over-the-counter opioid-reversal drugs is heating up, with Narcan maker’s application for approval getting priority review from the FDA
FDA’s priority review gives opioid-overdose reversal drug expected approval date of March 2023, company saysAsh Ponders for The Wall Street JournalNarcan, a nasal-spray form of naloxone, said Tuesday that the U.S. Food and Drug Administration fast-tracked an application it submitted for an over-the-counter version of its widely used opioid-reversal nasal spray.
The company said it had been working on the application for several months. Emergent said the FDA’s priority review gives the drug an expected approval date of March 29, 2023, putting it first in line for approval ahead of
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Trump Calls for ‘Termination’ of Constitution Over Twitter CensorshipDonald Trump called for the 'termination' of the Constitution following a report about Twitter suppressing an article about Hunter Biden before the 2020 election. See potential bias and similarities in coverage from NBCNews, foxheadlines, Newsweek:
Read more »
WSJ News Exclusive | Credit Suisse’s Investment Bank Spinoff Attracts Saudi Crown PrinceSaudi Arabia's crown prince and a U.S. private-equity firm run by Barclays PLC's former chief executive are among those preparing to invest in Credit Suisse's upstart investment bank
Read more »
WSJ News Exclusive | FTX Effort to Save Itself Failed on Questionable AssetsFTX tried to save itself by calling in collateral from its Alameda trading arm and showing it to investors as a sign of strength. It didn’t work, because the collateral’s value kept falling.
Read more »
WSJ News Exclusive | PepsiCo to Lay Off Hundreds of Workers in Headquarters RolesThe cuts will affect the company’s North America beverage business and its North America snacks and packaged-foods business, according to people familiar with the matter.
Read more »
WSJ News Exclusive | Most Colleges Give Inaccurate Price Details in Financial-Aid Letters, Federal Report FindsMore than 90% of colleges incorrectly detail costs in financial-aid letters, the U.S. Government Accountability Office says, slamming aid-package descriptions as inadequate and misleading
Read more »